Roledumab

Drug Profile

Roledumab

Alternative Names: ADNC; Anti-D monoclonal antibody - LFB; Anti-RhD-antibody; Anti-Rhesus-D-monoclonal-antibody-LFB; Dmatria; LFB-R593; Monoclonal-anti-D

Latest Information Update: 21 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator LFB Biotechnologies
  • Class Monoclonal antibodies
  • Mechanism of Action Rh-Hr blood group system inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Haemolytic disease of newborn

Most Recent Events

  • 21 Jul 2015 Roledumab is in active development for Haemolytic disease of newborn in Europe
  • 01 Apr 2014 Phase-II/III clinical trials in Haemolytic disease of newborn (Prevention) in France (IV)
  • 10 Feb 2009 Phase-I clinical trials in Haemolytic disease of newborn in France (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top